We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.34B
AUM Growth
-$262M
Cap. Flow
-$351M
Cap. Flow %
-15.04%
Top 10 Hldgs %
70.89%
Holding
36
New
3
Increased
7
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$97.8M
2
VTRS icon
Viatris
VTRS
+$46.9M
3
PBYI icon
Puma Biotechnology
PBYI
+$36.2M
4
TSRO
TESARO, Inc.
TSRO
+$35.3M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$29M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$124M
2
SHPG
Shire pic
SHPG
+$110M
3
NUVA
NuVasive, Inc.
NUVA
+$62.5M
4
MYGN icon
Myriad Genetics
MYGN
+$56.1M
5
CSII
Cardiovascular Systems, Inc.
CSII
+$53.3M

Sector Composition

Rank Sector Weight
1 Healthcare 69.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$581M 24.88%
2,000,000
+1,000,000
+100% +$285M
AGN
2
DELISTED
Allergan plc
AGN
$171M 7.34%
900,000
-105,000
-10% -$19.3M
HCA icon
3
HCA Healthcare
HCA
$88.4B
$139M 5.95%
1,000,000
-350,000
-26% -$43.6M
VTRS icon
4
Viatris
VTRS
$20.8B
$137M 5.87%
3,750,000
+1,250,000
+50% +$46.9M
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$137M 5.84%
3,500,000
+1,000,000
+40% +$35.3M
UHS icon
6
Universal Health Services
UHS
$10.2B
$115M 4.92%
900,000
– –
BIIB icon
7
Biogen
BIIB
$30.9B
$106M 4.54%
300,000
-150,000
-33% -$51.6M
MCK icon
8
McKesson
MCK
$104B
$99.5M 4.26%
+750,000
New +$97.8M
NKTR icon
9
Nektar Therapeutics
NKTR
$2.39B
$91.4M 3.91%
100,000
-33,333
-25% -$28.5M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$78.8M 3.37%
2,075,000
-125,000
-6% -$5.54M
MNTA
11
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$75.7M 3.24%
2,878,890
-176,110
-6% -$4.76M
PRGO icon
12
Perrigo
PRGO
$1.44B
$70.8M 3.03%
1,000,000
+75,000
+8% +$5.63M
ATRA icon
13
Atara Biotherapeutics
ATRA
$72.6M
$67M 2.87%
64,800
– –
BKD icon
14
Brookdale Senior Living
BKD
$3.55B
$63.9M 2.73%
6,500,000
– –
EVHC
15
DELISTED
Envision Healthcare Holdings Inc
EVHC
$62M 2.65%
1,355,000
-295,000
-18% -$13.3M
MDCO
16
DELISTED
Medicines Co
MDCO
$59.8M 2.56%
2,000,000
– –
AMAG
17
DELISTED
AMAG Pharmaceuticals
AMAG
$53M 2.27%
2,650,000
– –
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$51.4M 2.2%
1,750,000
+750,000
+75% +$29M
THC icon
19
Tenet Healthcare
THC
$22.2B
$44.1M 1.89%
1,550,000
-700,000
-31% -$23.1M
PBYI icon
20
Puma Biotechnology
PBYI
$398M
$34.4M 1.47%
+750,000
New +$36.2M
KTWO
21
DELISTED
K2M Group Holdings, Inc
KTWO
$27.4M 1.17%
1,000,000
-1,000,000
-50% -$23.4M
ZYME icon
22
Zymeworks
ZYME
$1.62B
$21.6M 0.92%
1,373,000
+123,000
+10% +$1.76M
EGRX
23
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$20.2M 0.87%
291,600
+30,500
+12% +$2.31M
ELGX
24
DELISTED
Endologix Inc
ELGX
$17.8M 0.76%
930,000
– –
STRO icon
25
Sutro Biopharma
STRO
$386M
$9M 0.39%
+60,000
New +$9.06M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Camber Capital Management held 36 positions worth $2.34B, down 10% from $2.6B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Camber Capital Management withdrew a net $351M in Q3 2018, closing 10 positions and reducing 9 holdings. Its most notable exit was Genomic Health, Inc., an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in McKesson worth $99.5M.

  • Camber Capital Management's largest Q3 2018 buy was McKesson: 750,000 shares worth $99.5M.
  • Camber Capital Management added most to Viatris in Q3 2018, an estimated $46.9M increase.
  • Camber Capital Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $51.6M.
  • Camber Capital Management fully exited Genomic Health, Inc. in Q3 2018, selling an estimated $124M.
  • Camber Capital Management's ten largest holdings make up 71% of its $2.34B portfolio in Q3 2018.
  • Camber Capital Management opened 3 new positions and closed 10 in Q3 2018.
  • Camber Capital Management's portfolio value fell 10% quarter-over-quarter to $2.34B.

Based on Camber Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.